Alogliptin benzoate (BioDeep_00000817677)
代谢物信息卡片
Alogliptin benzoate
化学式: C25H27N5O4 (461.20629420000006)
中文名称: 苯甲酸阿格列汀
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N.C1=CC=C(C=C1)C(=O)O
InChI: /m1./s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins
D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:72324
- KEGGdrug: D06553
- PubChem: 16088021
- ChEMBL: CHEMBL227529
- CAS: 850649-62-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Eiji Kutoh, Alexandra N Kuto, Midori Akiyama, Eri Ozawa, Rumi Kurihara. Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid.
European journal of clinical pharmacology.
2023 Jul; 79(7):947-959. doi:
10.1007/s00228-023-03506-3. [PMID: 37193913] - Kozo Okada, Shinnosuke Kikuchi, Shotaro Kuji, Naoki Nakayama, Nobuhiko Maejima, Yasushi Matsuzawa, Noriaki Iwahashi, Masami Kosuge, Toshiaki Ebina, Kazuo Kimura, Kouichi Tamura, Kiyoshi Hibi. Impact of early intervention with alogliptin on coronary plaque regression and stabilization in patients with acute coronary syndromes.
Atherosclerosis.
2022 Nov; 360(?):1-7. doi:
10.1016/j.atherosclerosis.2022.09.005. [PMID: 36191453] - Hae Jin Kim, In Kyung Jeong, Kyu Yeon Hur, Soo-Kyung Kim, Jung Hyun Noh, Sung Wan Chun, Eun Seok Kang, Eun-Jung Rhee, Sung Hee Choi. Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
Diabetes & metabolism journal.
2022 09; 46(5):689-700. doi:
10.4093/dmj.2021.0183. [PMID: 35295073] - Rania M Salama, Merihane M Nasr, Jannatullah I Abdelhakeem, Omar K Roshdy, Mohamed A ElGamal. Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade.
Drug and chemical toxicology.
2022 May; 45(3):1254-1263. doi:
10.1080/01480545.2020.1814319. [PMID: 32869669] - Azza S Tammam, Ahmed A Gahlan, Mahmoud A Taher, Ahmed M Haredy. Hantzsch condensation reaction as a spectrofluorometric method for determination of alogliptin, an antidiabetic drug, in pure form, tablet form, and human and rat plasma.
Luminescence : the journal of biological and chemical luminescence.
2022 Apr; 37(4):543-550. doi:
10.1002/bio.4178. [PMID: 34907663] - Ning Guo, Na Li, Yan Zhao, Huaibin Sun, Kao Liu. Effects of Systematic Diet Education Combined with Multidisciplinary Nursing on Nutritional Status and Calcium and Phosphorus Metabolism in Patients with Diabetic Kidney Disease in Uremic Phase after Treatment with Alogliptin.
Journal of healthcare engineering.
2022; 2022(?):1120242. doi:
10.1155/2022/1120242. [PMID: 35340239] - A M Kabel, H H Arab, M A Abd Elmaaboud. Attenuation of diethyl nitrosamine-induced hepatocellular carcinoma by taxifolin and/or alogliptin: The interplay between toll-like receptor 4, transforming growth factor beta-1, and apoptosis.
Human & experimental toxicology.
2021 Oct; 40(10):1710-1720. doi:
10.1177/09603271211008496. [PMID: 33840231] - Herbert Nar, Gisela Schnapp, Oliver Hucke, Timothy C Hardman, Thomas Klein. Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
ChemMedChem.
2021 05; 16(9):1425-1426. doi:
10.1002/cmdc.202000921. [PMID: 33348462] - Fumitaka Okajima, Hitoshi Sugihara, Naoya Emoto. Efficacy and Safety of Miglitol- or Repaglinide-Based Combination Therapy with Alogliptin for Drug-Naïve Patients with Type 2 Diabetes: An Open-Label, Single-Center, Parallel, Randomized Controlled Pilot Study.
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
2021 Mar; 88(1):71-79. doi:
10.1272/jnms.jnms.2021_88-205. [PMID: 32475902] - Shuangshuang Zhang, Ruixue Gan, Ludan Zhao, Qiaomei Sun, Hongzhao Xiang, Xi Xiang, Gang Zhao, Hui Li. Unveiling the interaction mechanism of alogliptin benzoate with human serum albumin: Insights from spectroscopy, microcalorimetry, and molecular docking and molecular dynamics analyses.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2021 Feb; 246(?):119040. doi:
10.1016/j.saa.2020.119040. [PMID: 33068900] - Shereen Mowaka, Nermeen Ashoush, Mariam Tadros, Noha El Zahar, Bassam Ayoub. Enhanced Extraction Technique of Omarigliptin from Human Plasma-Applied to Biological Samples from Healthy Human Volunteers.
Molecules (Basel, Switzerland).
2020 Sep; 25(18):. doi:
10.3390/molecules25184232. [PMID: 32942678] - Marina V Shestakova, Ekaterina A Shestakova, Vera A Kachko. [Specific features of the use of alogliptin in various groups of patients with type 2 diabetes mellitus: additional results of the ENTIRE study].
Problemy endokrinologii.
2020 08; 66(2):49-60. doi:
10.14341/probl12273. [PMID: 33351348] - João Pedro Ferreira, Cyrus Mehta, Abhinav Sharma, Steven E Nissen, Patrick Rossignol, Faiez Zannad. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial.
BMC medicine.
2020 06; 18(1):165. doi:
10.1186/s12916-020-01616-8. [PMID: 32493335] - Yayoi Nishida, Yasuo Takahashi, Kotoe Tezuka, Hayato Akimoto, Tomohiro Nakayama, Satoshi Asai. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
BMC pharmacology & toxicology.
2020 04; 21(1):28. doi:
10.1186/s40360-020-00407-4. [PMID: 32317005] - Heba A Aref, Sherin F Hammad, Khaled M Darwish, Mohammed S Elgawish. Novel spectrofluorimetric quantification of alogliptin benzoate in biofluids exploiting its interaction with 4-chloro-7-nitrobenzofurazan.
Luminescence : the journal of biological and chemical luminescence.
2020 Mar; 35(2):284-291. doi:
10.1002/bio.3725. [PMID: 31762136] - Jeong Mi Kim, Sang Soo Kim, Jong Ho Kim, Mi Kyung Kim, Tae Nyun Kim, Soon Hee Lee, Chang Won Lee, Ja Young Park, Eun Sook Kim, Kwang Jae Lee, Young Sik Choi, Duk Kyu Kim, In Joo Kim. Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study.
Diabetes & metabolism journal.
2020 02; 44(1):67-77. doi:
10.4093/dmj.2018.0274. [PMID: 31339011] - Khadiga M Kelani, Mamdouh R Rezk, Osama M Badran, Mohamed R Elghobashy. Determination of pioglitazone, its metabolite and alogliptin in human plasma by a novel LC-MS/MS method; application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Nov; 1132(?):121803. doi:
10.1016/j.jchromb.2019.121803. [PMID: 31704620] - Ying Han, Liqing Chen, Wei Liu, Xin Xin, Lingwei Meng, Xiaoyang Chu, Wei Huang, Mingji Jin, Zhonggao Gao. An HPLC-MS/MS method for quantitation of trelagliptin and application in a comparative pharmacokinetic study.
Bioanalysis.
2019 Oct; 11(19):1755-1765. doi:
10.4155/bio-2018-0238. [PMID: 31648536] - Motoaki Sano. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
Journal of cardiology.
2019 01; 73(1):28-32. doi:
10.1016/j.jjcc.2018.07.004. [PMID: 30318179] - Xiaowei Zhang, Zhiwei Zhang, Yajuan Yang, Ya Suo, Ruimeng Liu, Jiuchun Qiu, Yungang Zhao, Ning Jiang, Changle Liu, Gary Tse, Guangping Li, Tong Liu. Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits.
Cardiovascular diabetology.
2018 12; 17(1):160. doi:
10.1186/s12933-018-0803-z. [PMID: 30591063] - Yang Liu, Ling Song, Xueting Yao, Yiwen Wu, Hongzhong Liu, Qian Zhao, Ji Jiang, Chongtie Shi, Xifeng Ma, Huimin Zhou, Dongyang Liu, Pei Hu. A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple-dose pharmacokinetic study.
Biomedical chromatography : BMC.
2018 Nov; 32(11):e4324. doi:
10.1002/bmc.4324. [PMID: 29952007] - Akira Kurozumi, Yosuke Okada, Tadashi Arao, Takuya Kobayashi, Daisaku Masuda, Shizuya Yamashita, Yoshiya Tanaka. Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients.
Journal of diabetes investigation.
2018 Mar; 9(2):360-365. doi:
10.1111/jdi.12739. [PMID: 28853228] - David Paul, Lingesh Allakonda, Amit Sahu, Shruti Surendran, Nanjappan Satheeshkumar. Pharmacokinetics and brain uptake study of novel AMPA receptor antagonist perampanel in SD rats using a validated UHPLC-QTOF-MS method.
Journal of pharmaceutical and biomedical analysis.
2018 Feb; 149(?):234-241. doi:
10.1016/j.jpba.2017.11.008. [PMID: 29127904] - Ahmed M Kabel. Zinc/alogliptin combination attenuates testicular toxicity induced by doxorubicin in rats: Role of oxidative stress, apoptosis and TGF-β1/NF-κB signaling.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2018 Jan; 97(?):439-449. doi:
10.1016/j.biopha.2017.10.144. [PMID: 29091894] - Shinya Baba, Masamitsu Iwasa, Kenshi Higashi, Shingo Minatoguchi, Yoshihisa Yamada, Hiromitsu Kanamori, Masanori Kawasaki, Kazuhiko Nishigaki, Shinya Minatoguchi. Antidiabetic Drug Alogliptin Protects the Heart Against Ischemia-reperfusion Injury Through GLP-1 Receptor-dependent and Receptor-independent Pathways Involving Nitric Oxide Production in Rabbits.
Journal of cardiovascular pharmacology.
2017 Dec; 70(6):382-389. doi:
10.1097/fjc.0000000000000531. [PMID: 28817485] - Takahiro Uchida, Takashi Oda, Hidehito Matsubara, Atsushi Watanabe, Hanako Takechi, Naoki Oshima, Yutaka Sakurai, Hiroo Kumagai. Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis.
Renal failure.
2017 Nov; 39(1):340-349. doi:
10.1080/0886022x.2017.1279553. [PMID: 28118775] - Maha F Abdel-Ghany, Miriam F Ayad, Mariam M Tadros. Enhanced LC-MS/MS analysis of alogliptin and pioglitazone in human plasma: Applied to a preliminary pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2017 Jul; 1058(?):93-101. doi:
10.1016/j.jchromb.2017.04.043. [PMID: 28528664] - Xiaowei Zhang, Zhiwei Zhang, Yungang Zhao, Ning Jiang, Jiuchun Qiu, Yajuan Yang, Jian Li, Xue Liang, Xinghua Wang, Gary Tse, Guangping Li, Tong Liu. Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits.
Journal of the American Heart Association.
2017 May; 6(5):. doi:
10.1161/jaha.117.005945. [PMID: 28507060] - Changyu Pan, Ping Han, Qiuhe Ji, Chengjiang Li, Juming Lu, Jinkui Yang, Wenhui Li, Jiaoe Zeng, An-Tsz Hsieh, Juliana Chan. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Journal of diabetes.
2017 Apr; 9(4):386-395. doi:
10.1111/1753-0407.12425. [PMID: 27171508] - Caroline Dudkowski, Max Tsai, Jie Liu, Zhen Zhao, Eric Schmidt, Jeannie Xie. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
European journal of clinical pharmacology.
2017 Mar; 73(3):279-288. doi:
10.1007/s00228-016-2175-1. [PMID: 27999883] - Kenichi Tanaka, Yosuke Okada, Hiroko Mori, Megumi Miyazaki, Fumi Kuno, Satomi Sonoda, Kei Sugai, Maiko Hajime, Akira Kurozumi, Manabu Narisawa, Keiichi Torimoto, Tadashi Arao, Shinichiro Mine, Yoshiya Tanaka. Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.
Endocrine journal.
2017 Feb; 64(2):179-189. doi:
10.1507/endocrj.ej16-0341. [PMID: 27840383] - Maimaiti Yisireyili, Kyosuke Takeshita, Motoharu Hayashi, Hongxian Wu, Yasuhiro Uchida, Koji Yamamoto, Ryosuke Kikuchi, Chang-Ning Hao, Takayuki Nakayama, Xian Wu Cheng, Tadashi Matsushita, Shigeo Nakamura, Toyoaki Murohara. Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model.
Psychoneuroendocrinology.
2016 11; 73(?):186-195. doi:
10.1016/j.psyneuen.2016.08.004. [PMID: 27509090] - Abigail Tebboth, Sally Lee, Anna Scowcroft, Paula Bingham-Gardiner, Will Spencer, John Bolodeoku, Syed Wasi Hassan. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Clinical therapeutics.
2016 Aug; 38(8):1825-1832.e15. doi:
10.1016/j.clinthera.2016.07.006. [PMID: 27491279] - Dongyang Liu, Xifeng Ma, Yang Liu, Huimin Zhou, Chongtie Shi, Frank Wu, Ji Jiang, Pei Hu. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2016 Jun; 89(?):73-82. doi:
10.1016/j.ejps.2016.04.020. [PMID: 27108678] - Himanshu Naik, Richard Czerniak, Majid Vakilynejad. Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.
British journal of clinical pharmacology.
2016 Apr; 81(4):700-12. doi:
10.1111/bcp.12853. [PMID: 26617339] - M Kusunoki, D Sato, T Nakamura, Y Oshida, H Tsutsui, Y Natsume, K Tsutsumi, T Miyata. The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.
Drug research.
2016 Jan; 66(1):18-22. doi:
10.1055/s-0035-1547254. [PMID: 26125284] - Katsunori Nonogaki, Takao Kaji. Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.
Diabetes research and clinical practice.
2015 Dec; 110(3):e18-21. doi:
10.1016/j.diabres.2015.10.011. [PMID: 26497774] - K Nonogaki, T Kaji. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.
Diabetes & metabolism.
2015 Nov; 41(5):425-8. doi:
10.1016/j.diabet.2015.06.005. [PMID: 26234524] - Changyu Pan, Wenhui Li, Jiaoe Zeng, Chengjiang Li, Jinkui Yang, Qiuhe Ji, Juming Lu, Xiaofeng Lyu, Xuefeng Li, Shen Qu, Xiangjin Xu, Yaoming Xue, Ling Li, Zhaoshun Jiang, Baozhong Zheng, Ruifang Bu, Ping Han, Yu Liu, Jingdong Liu, Yongde Peng, Xiaomin Liu, Zhimin Liu, Li Yan, Minxiang Lei, Xuejun Li, Qinhua Song, Bingyin Shi, Wei Gu, Zhengfang Li. [Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
Zhonghua nei ke za zhi.
2015 Nov; 54(11):949-53. doi:
NULL. [PMID: 26759214] - Subbiah Pugazhenthi, LiMei Qin, Ron Bouchard. Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells.
European journal of pharmacology.
2015 May; 755(?):42-9. doi:
10.1016/j.ejphar.2015.02.024. [PMID: 25720341] - Motoh Iwasa, Tomoaki Ishihara, Rumi Mifuji-Moroka, Naoki Fujita, Yoshinao Kobayashi, Hiroshi Hasegawa, Kazuko Iwata, Masahiko Kaito, Yoshiyuki Takei. Elevation of branched-chain amino acid levels in diabetes and NAFL and changes with antidiabetic drug treatment.
Obesity research & clinical practice.
2015 May; 9(3):293-7. doi:
10.1016/j.orcp.2015.01.003. [PMID: 25649191] - Ying Cai, Todd A Lydic, Thomas Turkette, Gavin E Reid, L Karl Olson. Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats.
Biochemical pharmacology.
2015 May; 95(1):46-57. doi:
10.1016/j.bcp.2015.03.010. [PMID: 25801003] - Yoshiki Higashijima, Tetsuhiro Tanaka, Junna Yamaguchi, Shinji Tanaka, Masaomi Nangaku. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
American journal of physiology. Renal physiology.
2015 Apr; 308(8):F878-87. doi:
10.1152/ajprenal.00590.2014. [PMID: 25656369] - Koji Akita, Kikuo Isoda, Kazunori Shimada, Hiroyuki Daida. Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice.
Journal of the American Heart Association.
2015 Mar; 4(3):e001469. doi:
10.1161/jaha.114.001469. [PMID: 25770025] - Tomoko Mizushige, Hiroyuki Kobori, Yoko Nishijima, Yuichiro Yano, Koji Sakata, Manabu Hayakawa, Akira Nishiyama. Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.
Journal of diabetes research.
2015; 2015(?):517472. doi:
10.1155/2015/517472. [PMID: 26380312] - S Del Prato, R Camisasca, C Wilson, P Fleck. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Diabetes, obesity & metabolism.
2014 Dec; 16(12):1239-46. doi:
10.1111/dom.12377. [PMID: 25132212] - Zeng-Wei Lai, Chunhong Li, Jun Liu, Lingyi Kong, Xiaoan Wen, Hongbin Sun. Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
European journal of medicinal chemistry.
2014 Aug; 83(?):547-60. doi:
10.1016/j.ejmech.2014.06.044. [PMID: 24996141] - R E Pratley, P Fleck, C Wilson. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
Diabetes, obesity & metabolism.
2014 Jul; 16(7):613-21. doi:
10.1111/dom.12258. [PMID: 24400655] - Naro Ohashi, Naoko Tsuji, Yoshitaka Naito, Takamasa Iwakura, Shinsuke Isobe, Masafumi Ono, Tomoyuki Fujikura, Takayuki Tsuji, Yukitoshi Sakao, Hideo Yasuda, Akihiko Kato, Yoshihide Fujigaki. Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels.
Medical science monitor : international medical journal of experimental and clinical research.
2014 Apr; 20(?):587-93. doi:
10.12659/msm.889872. [PMID: 24717767] - Bethany P Cummings, Ahmed Bettaieb, James L Graham, Kimber Stanhope, Fawaz G Haj, Peter J Havel. Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.
The Journal of endocrinology.
2014 Apr; 221(1):133-44. doi:
10.1530/joe-13-0601. [PMID: 24627447] - Daniël H Van Raalte, Renate E van Genugten, Björn Eliasson, Diane L Möller-Goede, Andrea Mari, Andrea Tura, Craig Wilson, Penny Fleck, Marja R Taskinen, Ulf Smith, Michaela Diamant. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.
European journal of endocrinology.
2014 Apr; 170(4):565-74. doi:
10.1530/eje-13-0639. [PMID: 24421302] - Takahiro Masuda, Yiling Fu, Akiko Eguchi, Jan Czogalla, Michael A Rose, Alexander Kuczkowski, Maria Gerasimova, Ariel E Feldstein, Miriam Scadeng, Volker Vallon. Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention.
American journal of physiology. Endocrinology and metabolism.
2014 Feb; 306(4):E388-98. doi:
10.1152/ajpendo.00124.2013. [PMID: 24347054] - Yukinao Sakai, Anna Suzuki, Koji Mugishima, Yuichiro Sumi, Yusuke Otsuka, Tomoyuki Otsuka, Dai Ohno, Tsuneo Murasawa, Shuichi Tsuruoka. Effects of alogliptin in chronic kidney disease patients with type 2 diabetes.
Internal medicine (Tokyo, Japan).
2014; 53(3):195-203. doi:
10.2169/internalmedicine.53.1292. [PMID: 24492687] - Hiroki Fujita, Hisanori Taniai, Hiroko Murayama, Haruyo Ohshiro, Hikaru Hayashi, Seiko Sato, Nyuko Kikuchi, Taiga Komatsu, Koga Komatsu, Kanji Komatsu, Takuma Narita, Yuichiro Yamada. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
Endocrine journal.
2014; 61(2):159-66. doi:
10.1507/endocrj.ej13-0305. [PMID: 24225429] - Kohzo Takebayashi, Shintaro Sakurai, Tatsuhiko Suzuki, Kenichiro Hori, Tomoko Terasawa, Rika Naruse, Kenji Hara, Mariko Suetsugu, Takafumi Tsuchiya, Hiromi Aoki, Takashi Hamasaki, Hiroshi Shuutou, Toshihiko Inukai. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.
Endocrine journal.
2014; 61(10):1031-9. doi:
10.1507/endocrj.ej14-0208. [PMID: 25185672] - Daisuke Katagiri, Yoshifumi Hamasaki, Kent Doi, Koji Okamoto, Kousuke Negishi, Masaomi Nangaku, Eisei Noiri. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.
Journal of the American Society of Nephrology : JASN.
2013 Dec; 24(12):2034-43. doi:
10.1681/asn.2013020134. [PMID: 24092928] - Chang-yu Pan, Wen-hui Li, Jiao-e Zeng, Cheng-jiang Li, Jin-kui Yang, Qiu-he Ji, Ju-ming Lu, Xiao-feng Lü, Xue-feng Li, Shen Qu, Xiang-jin Xu, Yao-ming Xue, Ling Li, Zhao-shun Jiang, Bao-zhong Zheng, Rui-fang Bu, Ping Han, Yu Liu, Jing-dong Liu, Yong-de Peng, Xiao-min Liu, Zhi-min Liu, Li Yan, Min-xiang Lei, Xue-jun Li, Qin-hua Song, Bing-yin Shi, Wei Gu, Zheng-fang Li. [The design and baseline characteristics of a phase III study to evaluate the efficacy and safety of alogliptin versus placebo in type 2 diabetes mellitus in Mainland China].
Zhonghua nei ke za zhi.
2013 Nov; 52(11):932-5. doi:
NULL. [PMID: 24439186] - German Ramirez, Anthony D Morrison, Polly A Bittle. Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
2013 Nov; 19(6):1025-34. doi:
10.4158/ep12306.ra. [PMID: 23757605] - Koji Sakata, Manabu Hayakawa, Yuichiro Yano, Noboru Tamaki, Naoto Yokota, Takuma Eto, Reiko Watanabe, Naoteru Hirayama, Takeshi Matsuo, Kazuo Kuroki, Seiji Sagara, Osamu Mishima, Masahiro Koga, Naoto Nagata, Yuri Nishino, Kazuo Kitamura, Kazuomi Kario, Masayoshi Takeuchi, Sho-ichi Yamagishi. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes.
Diabetes/metabolism research and reviews.
2013 Nov; 29(8):624-30. doi:
10.1002/dmrr.2437. [PMID: 23861159] - Colleen Flynn, George L Bakris. Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Nature reviews. Nephrology.
2013 Mar; 9(3):147-53. doi:
10.1038/nrneph.2013.12. [PMID: 23358424] - Yuki Fujii, Masanori Abe, Terumi Higuchi, Mari Mizuno, Hiroko Suzuki, Shiro Matsumoto, Midori Ito, Noriaki Maruyama, Kazuyoshi Okada, Masayoshi Soma. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
Expert opinion on pharmacotherapy.
2013 Feb; 14(3):259-67. doi:
10.1517/14656566.2013.761690. [PMID: 23289982] - Yoko Noda, Toru Miyoshi, Hiroki Oe, Yuko Ohno, Kazufumi Nakamura, Norihisa Toh, Kunihisa Kohno, Hiroshi Morita, Kengo Kusano, Hiroshi Ito. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.
Cardiovascular diabetology.
2013 Jan; 12(?):8. doi:
10.1186/1475-2840-12-8. [PMID: 23298374] - Annalisa Capuano, Liberata Sportiello, Maria Ida Maiorino, Francesco Rossi, Dario Giugliano, Katherine Esposito. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
Drug design, development and therapy.
2013; 7(?):989-1001. doi:
10.2147/dddt.s37647. [PMID: 24068868] - Ritesh Agrawal, Radhe Shyam Bahare, Pratima Jain, Subodh Narayan Dikshit, Swastika Ganguly. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
Mini reviews in medicinal chemistry.
2012 Nov; 12(13):1345-58. doi:
10.2174/13895575112091345. [PMID: 22512582] - Timo Rieg, Maria Gerasimova, Fiona Murray, Takahiro Masuda, Tong Tang, Michael Rose, Daniel J Drucker, Volker Vallon. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
American journal of physiology. Renal physiology.
2012 Oct; 303(7):F963-71. doi:
10.1152/ajprenal.00259.2012. [PMID: 22832924] - Eiji Kutoh, Yasuhiro Ukai. Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.
Endocrine.
2012 Jun; 41(3):435-41. doi:
10.1007/s12020-012-9596-0. [PMID: 22249941] - R A DeFronzo, C F Burant, P Fleck, C Wilson, Q Mekki, R E Pratley. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism.
2012 May; 97(5):1615-22. doi:
10.1210/jc.2011-2243. [PMID: 22419732] - E Bosi, G C Ellis, C A Wilson, P R Fleck. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Diabetes, obesity & metabolism.
2011 Dec; 13(12):1088-96. doi:
10.1111/j.1463-1326.2011.01463.x. [PMID: 21733058] - Yutaka Seino, Tetsuya Fujita, Shinzo Hiroi, Masashi Hirayama, Kohei Kaku. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Current medical research and opinion.
2011 Nov; 27 Suppl 3(?):21-9. doi:
10.1185/03007995.2011.614936. [PMID: 22106975] - Yutaka Seino, Tetsuya Fujita, Shinzo Hiroi, Masashi Hirayama, Kohei Kaku. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
Current medical research and opinion.
2011 Sep; 27(9):1781-92. doi:
10.1185/03007995.2011.599371. [PMID: 21806314] - Nga N Ta, Corinne A Schuyler, Yanchun Li, Maria F Lopes-Virella, Yan Huang. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Journal of cardiovascular pharmacology.
2011 Aug; 58(2):157-66. doi:
10.1097/fjc.0b013e31821e5626. [PMID: 21558879] - X Zhang, Z Wang, Y Huang, J Wang. Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.
Diabetes, obesity & metabolism.
2011 Apr; 13(4):337-47. doi:
10.1111/j.1463-1326.2010.01354.x. [PMID: 21205126] - Lyubov Chaykovska, Karoline von Websky, Jan Rahnenführer, Markus Alter, Susi Heiden, Holger Fuchs, Frank Runge, Thomas Klein, Berthold Hocher. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
PloS one.
2011; 6(11):e27861. doi:
10.1371/journal.pone.0027861. [PMID: 22125632] - Julio Rosenstock, Silvio E Inzucchi, Jochen Seufert, Penny R Fleck, Craig A Wilson, Qais Mekki. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
Diabetes care.
2010 Nov; 33(11):2406-8. doi:
10.2337/dc10-0159. [PMID: 20724648] - Lesley J Scott. Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Drugs.
2010 Oct; 70(15):2051-72. doi:
10.2165/11205080-000000000-00000. [PMID: 20883057] - Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Vascular health and risk management.
2010 Sep; 6(?):671-90. doi:
10.2147/vhrm.s4852. [PMID: 20859539] - André J Scheen. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Clinical pharmacokinetics.
2010 Sep; 49(9):573-88. doi:
10.2165/11532980-000000000-00000. [PMID: 20690781] - Y Moritoh, K Takeuchi, M Hazama. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
Diabetes, obesity & metabolism.
2010 Mar; 12(3):224-33. doi:
10.1111/j.1463-1326.2009.01156.x. [PMID: 20151999] - A Karim, P Covington, R Christopher, M Davenport, P Fleck, X Li, E Wann, Q Mekki. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
International journal of clinical pharmacology and therapeutics.
2010 Jan; 48(1):46-58. doi:
10.5414/cpp48046. [PMID: 20040339] - Richard E Pratley, Thérèse McCall, Penny R Fleck, Craig A Wilson, Qais Mekki. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Journal of the American Geriatrics Society.
2009 Nov; 57(11):2011-9. doi:
10.1111/j.1532-5415.2009.02484.x. [PMID: 19793357] - Richard E Pratley, Jane E -B Reusch, Penny R Fleck, Craig A Wilson, Qais Mekki. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Current medical research and opinion.
2009 Oct; 25(10):2361-71. doi:
10.1185/03007990903156111. [PMID: 19650752] - Aziz Karim, Aziz Laurent, Melvin Munsaka, Elisabeth Wann, Penny Fleck, Qais Mekki. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Journal of clinical pharmacology.
2009 Oct; 49(10):1210-9. doi:
10.1177/0091270009338938. [PMID: 19622714] - Tomoko Asakawa, Yusuke Moritoh, Osamu Kataoka, Nobuhiro Suzuki, Koji Takeuchi, Hiroyuki Odaka. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
Life sciences.
2009 Jul; 85(3-4):122-6. doi:
10.1016/j.lfs.2009.04.024. [PMID: 19427871] - Y Moritoh, K Takeuchi, T Asakawa, O Kataoka, H Odaka. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
British journal of pharmacology.
2009 Jun; 157(3):415-26. doi:
10.1111/j.1476-5381.2009.00145.x. [PMID: 19371350] - R E Pratley, M S Kipnes, P R Fleck, C Wilson, Q Mekki. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Diabetes, obesity & metabolism.
2009 Feb; 11(2):167-76. doi:
10.1111/j.1463-1326.2008.01016.x. [PMID: 19125778] - Yusuke Moritoh, Koji Takeuchi, Tomoko Asakawa, Osamu Kataoka, Hiroyuki Odaka. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
European journal of pharmacology.
2009 Jan; 602(2-3):448-54. doi:
10.1016/j.ejphar.2008.11.017. [PMID: 19038243] - M A Nauck, G C Ellis, P R Fleck, C A Wilson, Q Mekki. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
International journal of clinical practice.
2009 Jan; 63(1):46-55. doi:
10.1111/j.1742-1241.2008.01933.x. [PMID: 19125992] - Ralph A DeFronzo, Penny R Fleck, Craig A Wilson, Qais Mekki. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
Diabetes care.
2008 Dec; 31(12):2315-7. doi:
10.2337/dc08-1035. [PMID: 18809631] - Bumsup Lee, Lihong Shi, Daniel B Kassel, Tomoko Asakawa, Koji Takeuchi, Ronald J Christopher. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
European journal of pharmacology.
2008 Jul; 589(1-3):306-14. doi:
10.1016/j.ejphar.2008.04.047. [PMID: 18538760] - Yusuke Moritoh, Koji Takeuchi, Tomoko Asakawa, Osamu Kataoka, Hiroyuki Odaka. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
European journal of pharmacology.
2008 Jul; 588(2-3):325-32. doi:
10.1016/j.ejphar.2008.04.018. [PMID: 18499100] - Paul Covington, Ronald Christopher, Michael Davenport, Penny Fleck, Qais A Mekki, Elisabeth R Wann, Aziz Karim. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Clinical therapeutics.
2008 Mar; 30(3):499-512. doi:
10.1016/j.clinthera.2008.03.004. [PMID: 18405788] - Ronald Christopher, Paul Covington, Michael Davenport, Penny Fleck, Qais A Mekki, Elisabeth R Wann, Aziz Karim. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Clinical therapeutics.
2008 Mar; 30(3):513-27. doi:
10.1016/j.clinthera.2008.03.005. [PMID: 18405789] - Jun Feng, Zhiyuan Zhang, Michael B Wallace, Jeffrey A Stafford, Stephen W Kaldor, Daniel B Kassel, Marc Navre, Lihong Shi, Robert J Skene, Tomoko Asakawa, Koji Takeuchi, Rongda Xu, David R Webb, Stephen L Gwaltney. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Journal of medicinal chemistry.
2007 May; 50(10):2297-300. doi:
10.1021/jm070104l. [PMID: 17441705]